The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
作者:Katherine A. Michaelis[1];Mason A. Norgard[2];Xinxia Zhu[2];Peter R. Levasseur[2];Shamilene Sivagnanam[3];Shannon M. Liudahl[4];Kevin G. Burfeind[1];Brennan Olson[1];Katherine R. Pelz[2];Diana M. Angeles Ramos[2];H. Carlo Maurer[5];Kenneth P. Olive[5];Lisa M. Coussens[4];Terry K. Morgan[6];Daniel L. Marks[7]
DOI:10.1038/s41467-019-12657-w